Role of DNA Repair in Antitumour Effects of Platinum Drugs

Metal Complex-DNA Interactions

Volumn , Issue , 2009, Pages 175-208

  Brabec, Viktor ^a   Kašpárková, Jana ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

Author keywords

Antitumour platinum compound design; Base excision repair; Base excision repair system; Chemotherapeutic agents damaging DNA; Direct reversal of damage; DNA repair in antitumour effects of platinum drugs; Human DNA repair systems; Nonhomologous end joining mechanism in mammalian cells; Nucleotide excision repair

Indexed keywords

EID: 77953361196     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444312089.ch6     Document Type: Chapter

References (154)

1. Johnson, N.P.; Butour, J.-L.; Villani, G.; Wimmer, F.L.; Defais, M.; Pierson, V.; Brabec, V.; Metal antitumor compounds: The mechanism of action of platinum complexes; Prog. Clin. Biochem. Med., 1989, 10, 1-24.
2. Brabec, V.; Kasparkova, J.; DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action; In Metal Compounds in Cancer Chemotherapy, Perez-Martin, J.-M., Fuertes, M.A. and Alonso, C., Eds., Research Signpost, Trivandrum, Kerala (India), 2005, 187-218.
3. Brabec, V.; DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair; Prog. Nucleic Acid Res. Mol. Biol., 2002, 71, 1-68.
4. Siddik, Z.H.; Cisplatin: mode of cytotoxic action and molecular basis of resistance; Oncogene, 2003, 22, 7265-7279.
5. Brabec, V.; Kleinwächter, V.; Butour, J.L.; Johnson, N.P.; Biophysical studies of the modification of DNA by antitumour platinum coordination complexes; Biophys. Chem., 1990, 35, 129-141.
6. Jamieson, E.R.; Lippard, S.J.; Structure, recognition, and processing of cisplatin-DNA adducts; Chem. Rev, 1999, 99, 2467-2498.
7. Friedberg, E.C.; A brief history of the DNA repair field; Cell Res., 2008, 18, 3-7.
8. Watanabe, T.; Sullenger, B.A.; RNA repair: a novel approach to gene therapy; Adv. Drug Deliv. Rev., 2000, 44, 109-118.
9. Bellacosa, A.; Moss, E.G.; RNA repair: Damage control; Curr. Biol., 2003, 13, R482-R484.
10. Wang, L.K.; Lima, C.D.; Shuman, S.; Structure and mechanism of T4 polynucleotide kinase: an RNA repair enzyme; EMBO J., 2002, 21, 3873-3880.
11. Pelletier, H.; Sawaya, M.R.; Wolfle, W.; Wilson, S.H.; Kraut, J.; Crystal structures of human DNA polymerase b complexed with DNA: Implications for catalytic mechanism, processivity, and fidelity; Biochemistry, 1996, 35, 12742-12761.
12. Sharma, R.A.; Dianov, G.L.; Targeting base excision repair to improve cancer therapies; Mol. Aspects Med., 2007, 28, 345-374.
13. Hutsell, S.Q.; Sancar, A.; Nucleotide excision repair, oxidative damage, DNA sequence polymorphisms, and cancer treatment; Clin. Cancer Res., 2005, 11, 1355-1357.
14. Kulaksiz, G.; Reardon, J.T.; Sancar, A.; Xeroderma pigmentosum complementationgroup E protein (XPE/DDB2): Purification of various complexes of XPE and analyses of their damaged DNA binding and putative DNA repair properties; Mol. Cell. Biol., 2005, 25, 9784-9792.
15. Keeney, S.; Eker, A.P.M.; Brody, T.; Vermeulen, W.; Bootsma, D.; Hoeijmakers, J.H.J.; Linn, S.; Correction of the DNA repair defect in xeroderma pigmentosum group E by injection of a DNA damage-binding protein. Proc. Natl. Acad. Sci. USA; 1994, 91, 4053-4056.
16. Itoh, T.; Linn, S.; Ono, T.; Yamaizumi, M.; Reinvestigation of the classification of five cell strains of xeroderma pigmentosum group E with reclassification of three of them; J. Investig. Dermatol., 2000, 114, 1022-1029.
17. Reardon, J.T.; Sancar, A.; Recognition and repair of the cyclobutane thymine dimer, a major cause of skin cancers, by the human excision nuclease; Genes Dev., 2003, 17, 2539-2551.
18. Reardon, J.T.; Sancar, A.; Nucleotide excision repair; Prog. Nucleic Acid Res. Mol. Biol., 2005, 79, 183-235.
19. Jiricny, J.; The multifaceted mismatch-repair system; Nature Rev. Mol. Cell Biol., 2006, 7, 335-346.
20. Iyer, R.R.; Pluciennik, A.; Burdett, V.; Modrich, PL.; DNA mismatch repair: Functions and mechanisms; Chem. Rev., 2006, 106, 302-323.
21. Pani, E.; Stojic, L.; El-Shemerly, M.; Jiricny, J.; Ferrari, S.; Mismatch repair status and the response of human cells to cisplatin; Cell Cycle, 2007, 6, 1796-1802.
22. Stojic, L.; Brun, R.; Jiricny, J.; Mismatch repair and DNA damage signalling; DNA Repair, 2004, 3, 1091-1101.
23. Dzantiev, L.; Constantin, N.; Genschel, J.; Iyer, R.R.; Burgers, P.M.; Modrich, P.; Defined human system that supports bidirectional mismatch-provoked excision; Mol. Cell, 2004, 15, 31-41.
24. Genschel, J.; Modrich, P.; Mechanism of 5'-directed excision in human mismatch repair; Mol. Cell, 2003, 12, 1077-1086.
25. Budman, J.; Chu, G.; Processing of DNA for nonhomologous end-joining by cell-free extract; EMBO J., 2005, 23, 849-860.
26. Boeckman, H. J.; Trego, K.S.; Turchi, J.J.; Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining; Mol. Cancer Res., 2005, 3, 277-285.
27. Diggle, C.P; Bentley, J.; Knowles, M.A.; Kiltie, A.E.; Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts; Nucleic Acids Res., 2005, 33, 2531-2539.
28. Pastwa, E.; Malinowski, M.; Non-homologous DNA end joining in anticancer therapy; Curr. Cancer Drug Targets, 2007, 7, 243-250.
29. Downs, J.A.; Jackson, S.P.; A means to a DNA end: The many roles of Ku; Nature Rev. Mol. Cell Biol., 2004, 5, 367-378.
30. Collis, S.J.; DeWeese, T.L.; Jeggo, P.A.; Parker, A.R.; The life and death of DNA-PK; Oncogene, 2005, 24, 949-961.
31. Drouet, J.; Frit, P.; Delteil, C.; de Villartay, J.P.; Salles, B.; Calsou, P.; Interplay between Ku, artemis, and the DNA-dependent protein kinase catalytic subunit at DNA ends; J. Biol. Chem, 2006, 281, 27784-27793.
32. Goodarzi, A.A.; Yu, Y.P; Riballo, E.; Douglas, P.; Walker, S.A.; Ye, R.Q.; Harer, C.; Mar-chetti, C.; Morrice, N.; Jeggo, P.A.; Lees-Miller, S.P; DNA-PK autophosphorylation facilitates Artemis endonuclease activity; EMBO J., 2006, 25, 3880-3889.
33. Grawunder, U.; Zimmer, D.; Fugmann, S.; Schwarz, K.; Lieber, M.R.; DNA ligase IV is essential for V(D)J recombination and DNA double-strand break repair in human precursor lymphocytes; Mol. Cell, 1998, 2, 477-484.
34. Ahnesorg, P.; Smith, P.; Jackson, S.P; XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining; Cell, 2006, 124, 301-313.
35. Daley, J.M.; Vander Laan, R.L.; Suresh, A.; Wilson, T.E.; DNA joint dependence of Pol X family polymerase action in nonhomologous end joining; J. Biol. Chem., 2005, 280, 29030-29037.
36. Xu, Z.-Y., Loignon, M.; Han, F.-Y., Panasci, L.; Aloyz, R.; Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis; J. Pharmacol. Exp. Ther., 2005, 314, 495-505.
37. West, S.C.; Molecular views of recombination proteins and their control; Nature Rev. Mol. Cell Biol., 2003, 4, 435-445.
38. Yang, W.; Woodgate, R.; What a difference a decade makes: Insights into translesion DNA synthesis; Proc. Natl. Acad. Sci. USA, 2007, 104, 15591-15598.
39. Fichtinger-Schepman, A.M.J.; Van der Veer, J.L.; Den Hartog, J.H.J.; Lohman, P.H.M.; Reedijk, J.; Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation; Biochemistry, 1985, 24, 707-713.
40. Eastman, A.; The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes; Pharmacol. Ther., 1987, 34, 155-166.
41. Lemaire, M.A.; Schwartz, A.; Rahmouni, A.R.; Leng, M.; Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloro platinum(II) and DNA; Proc. Natl. Acad. Sci. USA, 1991, 88, 1982-1985.
42. Gelasco, A.; Lippard, S.J.; Anticancer activity of cisplatin and related complexes. In Metallopharmaceuticals I. DNA Interactions, Clarke, M.J. and Sadler, P.J.; Eds., Springer, Berlin, 1999, 1-43.
43. Brabec, V.; Chemistry and structural biology of 1, 2-interstrand adducts of cisplatin; In Platinum-based Drugs in Cancer Therapy, Kelland, L.R. and Farrell, N.P.; Eds., Humana Press Inc., Totowa, NJ, 2000, 37-61.
44. Teuben, J.M.; Bauer, C.; Wang, A.H.J.; Reedijk, J.; Solution structure of a DNA duplex containing a cis-diammineplatinum(II) 1, 3-d(GTG) intrastrand cross-link, a major adduct in cells treated with the anticancer drug carboplatin; Biochemistry, 1999, 38, 12305-12312.
45. Brabec, V.; Reedijk, J.; Leng, M.; Sequence-dependent distortions induced in DNA by mono functional platinum(II) binding; Biochemistry, 1992, 31, 12397-12402.
46. Brabec, V.; Boudny, V.; Balcarova, Z.; Mono functional adducts of platinum(II) produce in DNA a sequence-dependent local denaturation; Biochemistry, 1994, 33, 1316-1322.
47. Blommaert, F.A.; van Dijk-Knijnenburg, H.C.M.; Dijt, F.J.; Denengelse, L.; Baan, R.A.; Berends, F.; Fichtinger-Schepman, A.M.J.; Formation of DNA adducts by the anticancer drug carboplatin: Different nucleotide sequence preferences in vitro and in cells; Biochemistry, 1995, 34, 8474-8480.
48. Woynarowski, J.M.; Chapman, W.G.; Napier, C.; Herzig, M.C.S.; Juniewicz, P.; Sequence-and region-specificity of oxaliplatin adducts in naked and cellular DNA; Mol. Pharmacol., 1998, 54, 770-777.
49. Woynarowski, J.M.; Faivre, S.; Herzig, M.C.S.; Arnett, B.; Chapman, W.G.; Trevino, A.V.; Raymond, E.; Chaney, S.G.; Vaisman, A.; Varchenko, M.; Juniewicz, P.E.; Oxaliplatin-induced damage of cellular DNA; Mol. Pharmacol., 2000, 58, 920-927.
50. Zlatanova, J.; Van Holde, K.; Binding to four-way junction DNA: A common property of architectural proteins?; FASEB J., 1998, 12, 421-431.
51. Missura, M.; Buterin, T.; Hindges, R.; Hubscher, U.; Kasparkova, J.; Brabec, V.; Naegeli, H.; Double-check probing of DNA bending and unwinding by XPA-RPA: an architectural function in DNA repair; EMBO J.; 2001, 20, 3554-3564.
52. Kasparkova, J.; Mellish, K.J.; Qu, Y.; Brabec, V.; Farrell, N.; Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes. Bending and NMR studies; Biochemistry, 1996, 35, 16705-16713.
53. Patrick, S.M.; Turchi; J.J.; Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA; J. Biol. Chem, 1999, 274, 14972-14978.
54. Hofr, C.; Farrell, N.; Brabec, V.; Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex; NucleicAcids Res., 2001, 29, 2034-2040.
55. Lao, Y.; Gomes, X.V.; Ren, Y.J.; Taylor, J.S.; Wold, M.S.; Replication protein A interactions with DNA. III. Molecular basis of recognition of damaged DNA; Biochemistry, 2000, 39, 850-859.
56. Hermanson-Miller, I.L.; Turchi, J.J.; Strand-specific binding of RPA and XPA to damaged duplex DNA; Biochemistry, 2002, 41, 2402-2408.
57. Patrick, S.M.; Turchi, J.J.; Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity; J. Biol. Chem., 2002, 277, 16096-16101.
58. Payne, A.; Chu, G.; Xeroderma pigmentosum group e binding factor recognizes a broad spectrum of DNA damage; Mutation Res., 1994, 31θ , 89-102.
59. Brabec, V.; Stehlikova, K.; Malina, J.; Vojtiskova, M.; Kasparkova, J.; Thermodynamic properties of damaged DNA and its recognition by xeroderma pigmentosum group A protein and replication protein A; Arch. Biochem. Biophys., 2006, 446, 1-10.
60. Hey, T.; Lipps, G.; Sugasawa, K.; Iwai, S.; Hanaoka, F.; Krauss, G.; The XPC-HR23B complex displays high affinity and specificity for damaged DNA in a true-equilibrium fluorescence assay; Biochemistry, 2002, 41, 6583-6587.
61. Zamble, D.B.; Mu, D.; Reardon, J.T.; Sancar, A.; Lippard, S.J.; Repair of cisplatin-DNA adducts by the mammalian excision nuclease; Biochemistry, 1996, 35, 10004-10013.
62. Kasparkova, J.; Zehnulova, J.; Farrell, N.; Brabec, V.; DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair; J. Biol. Chem., 2002, 277, 48076-48086.
63. Zehnulova, J.; Kasparkova, J.; Farrell, N.; Brabec, V.; Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464; J. Biol. Chem., 2001, 276, 22191-22199.
64. Tornaletti, S.; Patrick, S.M.; Turchi, J.J.; Hanawalt, P.C.; Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA; J. Biol. Chem, 2003, 278, 35791-35797.
65. Laine, J.P.; Egly, J.M.; Initiation of DNA repair mediated by a stalled RNA polymerase IIO; EMBO J., 2006, 25, 387-397.
66. Jung, Y.; Lippard, S.J.; RNA polymerase II blockage by cisplatin-damaged DNA-Stability and polyubiquitylation of stalled polymerase; J. Biol. Chem., 2006, 281, 1361-1370.
67. Damsma, G.E.; Alt, A.; Brueckner, F.; Carell, T.; Cramer, P.; Mechanism of transcriptional stalling at cisplatin-damaged DNA; Nature Struct. Mol. Biol., 2007, 14, 1127-1133.
68. Flohr, C.; Burkle, A.; Radicella, J.P.; Epe, B.; Poly(ADP-ribosyl)ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein; Nucleic Acids Res., 2003, 31, 5332-5337.
69. Zhang, C.X.; Chang, P.V.; Lippard, S.J.; Identification of nuclear proteins that interact with platinum-modified DNA by photoaffinity labeling; J. Am. Chem. Soc., 2004, 126, 6536-6537.
70. Mello, J.A.; Acharya, S.; Fishel, R.; Essigmann, J.M.; The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin; Chem. Biol., 1996, 3, 579-589.
71. Vaisman, A.; Varchenko, M.; Umar, A.; Kunkel, T.A.; Risinger, J.I.; Barrett, J.C.; Hamilton, T.C.; Chaney, S.G.; The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts; Cancer Res., 1998, 58, 3579-3585.
72. 4-methylthymine, or the cisplatin-d(GpG) adduct; Proc. Natl. Acad. Sci. USA, 1996, 93, 6443-6447.
73. Mu, D.; Tursun, M.; Duckett, D.R.; Drummond, J.T.; Modrich, P.; Sancar, A.; Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems; Mol. Cell. Biol., 1997, 17, 760-769.
74. Yamada, M.; O'Regan, E.; Brown, R.; Karran, P.; Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins; Nucleic Acids Res., 1997, 25, 491-495.
75. Turchi, J.J.; Henkels, K.; Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase; J. Biol. Chem., 1996, 271, 13861-13867.
76. Turchi, J.J.; Patrick, S.M.; Henkels, K.M.; Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)-damaged DNA; Biochemistry, 1997, 36, 7586-7593.
77. Kysela, B.; Doherty, A.J.; Chovanec, M.; Stiff, T.; Ameer-Beg, S.M.; Vojnovic, B.; Girard, P.-M.; Jeggo, P.A.; Ku stimulation of DNA ligase IV-dependent ligation requires inward movement along the DNA molecule; J. Biol. Chem., 2003, 278, 22466-22474.
78. Turchi, J.J.; Henkels, K.M.; Zhou, Y.; Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK; Nucleic Acids Res., 2000, 28, 4634-4641.
79. Noll, D.M.; Mason, T.M.; Miller, P.S.; Formation and repair of interstrand cross-links in DNA; Chem. Rev., 2006, 106, 277-301.
80. Vaisman, A.; Lim, S.E.; Patrick, S.M.; Copeland, W.C.; Hinkle, D.C.; Turchi, J.J.; Chaney, S.G.; Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts; Biochemistry, 1999, 38, 11026-11039.
81. Bassett, E.; Vaisman, A.; Havener, J.M.; Masutani, C.; Hanaoka, F.; Chaney, S.G.; Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta ; n vitro; Biochemistry, 2003, 42, 14197-14206.
82. Vaisman, A.; Chaney, S.G.; The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta; J. Biol. Chem., 2000, 275, 13017-13025.
83. Vaisman, A.; Masutani, C.; Hanaoka, F.; Chaney, S.G.; Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase η Biochemistry, 2000, 39, 4575-4580.
84. Havener, J.M.; McElhinny, S.A.N.; Bassett, E.; Gauger, M.; Ramsden, D.A.; Chaney, S.G.; Translesion synthesis past platinum DNA adducts by human DNA polymerase mu; Biochemistry, 2003, 42, 1777-1788.
85. Bassett, E.; King, N.M.; Bryant, M.F.; Hector, S.; Pendyala, L.; Chaney, S.G.; Cordeiro-Stone, M.; The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts; Cancer Res., 2004, 64, 6469-6475.
86. Daube, S.S.; Tomer, G.; Livneh, Z.; Translesion replication by DNA polymerase delta depends on processivity accessory proteins and differs in specificity from DNA polymerase beta; Biochemistry, 2000, 39, 348-355.
87. Prakash, S.; Prakash, L.; Translesion DNA synthesis in eukaryotes: A one-or two-polymerase affair; Gene Dev., 2002, 16, 1872-1883.
88. Wu, F.; Lin, X.J.; Okuda, T.; Howell, S.B.; DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance; Cancer Res., 2004, 64, 8029-8035.
89. Prakash, S.; Johnson, R.E.; Prakash, L.; Eukaryotic translesion synthesis DNA polymerases: Specificity of structure and function; Annu. Rev. Biochem., 2005, 74, 317-353.
90. Dronkert, M.L.G.; Kanaar, R.; Repair of DNA interstrand cross-links; Mutation Res., 2001, 486, 217-247.
91. Chaney, S.G.; Campbell, S.L.; Bassett, E.; Wu, Y.; Recognition and processing of cisplatin-and oxaliplatin-DNA adducts; Crit. Rev. Oncol. Hematol., 2005, 53, 3-11.
92. Cao, S.; Bendall, H.; Hicks, G.G.; Nashabi, A.; Sakano, H.; Shinkai, Y.; Gariglio, M.; Oltz, E.M.; Ruley, H.E.; The high-mobility-group box protein SSRP1/T160 is essential for cell viability in day 3.5 mouse embryos; Mol. Cell. Biol., 2003, 23, 5301-5307.
93. Krohn, N.M.; Stemmer, C.; Fojan, P.; Grimm, R.; Grasser, K.D.; Protein kinase CK2 phosphorylates the high mobility group domain protein SSRP1, inducing the recognition of UV-damaged DNA; J. Biol. Chem., 2003, 278, 12710-12715.
94. Toney, J.H.; Donahue, B.A.; Kellett, P.J.; Bruhn, S.L.; Essigmann, J.M.; Lippard, S.J.; Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II); Proc. Nat. Acad. Sci. USA, 1989, 89, 8328-8332.
95. Yarnell, A.T.; Oh, S.; Reinberg, D.; Lippard, S.J.; Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin; J. Biol. Chem., 2001, 276, 25736-25741.
96. Kartalou, M.; Samson, L.D.; Essigmann, J.M.; Cisplatin adducts inhibit 1, N-6-ethenoad-enine repair by interacting with the human 3-methyladenine DNA glycosylase; Biochemistry, 2000, 39, 8032-8038.
97. Kartalou, M.; Essigmann, J.M.; Recognition of cisplatin adducts by cellular proteins; Mutation Res., 2001, 478, 1-21.
98. Wozniak, K.; Blasiak, J.; Recognition and repair of DNA-cisplatin adducts; ActaBiochim. Pol, 2002, 49, 583-596.
99. Bellon, S.F.; Coleman, J.H.; Lippard, S.J.; DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II); Biochemistry, 1991, 30, 8026-8035.
100. +; Biophys. Chem., 1990, 35, 179-188.
101. Huang, J.C.; Zamble, D.B.; Reardon, J.T.; Lippard, S.J.; Sancar, A.; HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease; Proc. Natl. Acad. Sci. USA, 1994, 91, 10394-10398.
102. Plooy, A.C.M.; Fichtinger-Schepman, A.M.J.; Schutte, H.H.; van Dijk, M.; Lohman, P.H.M.; The quantitative detection of various Pt-DNA-adducts in chinese hamster ovary cells treated with cisplatin;application of immunochemical techniques; Carcinogenesis, 1985, 6, 561-566.
103. Dijt, F.J.; Fichtinger-Schepman, A.M.J.; Berends, F.; Reedijk, J.; Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts; Cancer Res., 1988, 48, 6058-6062.
104. Fujiwara, Y.; Tatsumi, M.; Sasaki, M.S.; Cross-link repair in human cells and its possible defect in Fanconi's anemia cells; J. Mol. Biol., 1977, 113, 635-649.
105. Calsou, P.; Frit, P.; Salles, B.; Repair synthesis by human cell extracts in cisplatin-damaged DNA is prefentially determined by minor adducts; Nucleic Acids Res., 1992, 20, 6363-6368.
106. Fisher, L.A.; Bessho, M.; Bessho, T.; Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro; J. Biol. Chem, 2008, 283, 1275-1281.
107. Chvalova, K.; Brabec, V.; Kasparkova, J.; Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin; Nucleic Acids Res., 2007, 35, 1812-1821.
108. Olinski, R.; Wedrychovski, A.; Schmidt, W.N.; Briggs, R.C.; Hnilica, L.S.; In vivo DNA-protein cross-linking by cis-and trans-diamminedichloroplatinum(II); Cancer Res., 1987, 47, 201-205.
109. Plooy, A.C.M.; Van Dijk, M.; Lohman, P.H.M.; Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity; Cancer Res., 1984, 44, 2043-2051.
110. Olinski, R.; Briggs, R.C.; DNA-protein cross-linking in L1210 cells and resistant to cis-diamminedichloroplatinum(II); Mol. Biol. Rep., 1991, 15, 81-86.
111. Richmond, T.J.; Davey, C.A.; The structure of DNA in the nucleosome core; Nature, 2003, 423, 145-150.
112. Wang, D.; Hara, R.; Singh, G.; Sancar, A.; Lippard, S.J.; Nucleotide excision repair from site-specifically platinum-modified nucleosomes; Biochemistry, 2003, 42, 6747-6753.
113. Reardon, J.T.; Vaisman, A.; Chaney, S.G.; Sancar, A.; Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts; Cancer Res., 1999, 59, 3968-3971.
114. 2, a metabolite of an orally active platinum anticancer drug; J. Am. Chem. Soc., 1992, 114, 5646-5654.
115. Malina, J.; Novakova, O.; Vojtiskova, M.; Natile, G.; Brabec, V.; Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog; Biophys. J., 2007, 93, 3950-3962.
116. Malina, J.; Hofr, C.; Maresca, L.; Natile, G.; Brabec, V.; DNA interactions of antitumor cisplatin analogs containing enantiomeric amine ligands; Biophys. J., 2000, 78, 2008-2021.
117. Malina, J.; Kasparkova, J.; Natile, G.; Brabec, V.; Recognition of major DNA adducts of enantiomeric cisplatin analogs by HMG box proteins and nucleotide excision repair of these adducts; Chem. Biol., 2002, 9, 629-638.
118. Delalande, O.; Malina, J.; Brabec, V.; Kozelka, J.; Chiral differentiation of DNA adducts formed by enantiomeric analogues of antitumor cisplatin is sequence-dependent; Biophys. J., 2005, 88, 4159-4169.
119. Reedijk, J.; Improved understanding in platinum antitumour chemistry; Chem. Commun., 1996, 1996-801.
120. Farrell, N.; Current status of structure-activity relationships of platinum anticancer drugs: Activation of the trans geometry. In Metal Ions in Biological Systems, Vol. 32, Sigel, A. and Sigel; H.; Eds., Marcel Dekker, Inc.; New York, Basel, Hong Kong; 1996, 603-639.
121. Coluccia, M.; Natile, G.; Trans-platinum complexes in cancer therapy; Anti-Cancer Agents Med. Chem., 2007, 7, 111-123.
122. Kasparkova, J.; Novakova, O.; Marini, V.; Najajreh, Y.; Gibson, D.; Perez, J.-M.; Brabec, V.; Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: Mechanistic studies on antitumor action; J. Biol. Chem., 2003, 278, 47516-47525.
123. 3)(thiazole)]; Nucleic Acids Res., 2005, 33, 5819-5828.
124. Coluccia, M.; Nassii, F.; Loseto, F.; Boccarelli, A.; Marigió, M.A.; Giordano, D.; Intini, F.P.; Caputo, P.; Natile, G.; A trans-platinum complex showing higher antitumor activity than the cis congeners; J. Med. Chem., 1993, 36, 510-512.
125. 2]; Nucleic Acids Res., 1996, 24, 336-341.
126. 2]. A concept for activation of the trans geometry in platinum antitumor complexes; Nucleic Acids Res., 2003, 31, 6450-6460.
127. Farrell, N.; Polynuclear platinum drugs. In Metal Ions in Biological Systems, Vol. 42, Sigel, A. and Sigel, H.; Eds., Marcel Dekker, Inc., New York, Basel, 2004, 251-296.
128. Perego, P.; Gatti, L.; Caserini, C.; Supino, R.; Colangelo, D.; Leone, R.; Spinelli, S.; Farrell, N.; Zunino, F.; The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells; J. Inorg. Biochem., 1999, 77, 59-64.
129. Roberts, J.D.; Beggiolin, G.; Manzotti, C.; Piazzoni, L.; Farrell, N.; Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines; J. Inorg. Biochem., 1999, 77, 47-50.
130. Farrell, N.; Polynuclear charged platinum compounds as a new class of anticancer agents: Toward a new paradigm. In Platinum-based Drugs in Cancer Therapy, Kelland, L.R. and Farrell, N.P.; Eds., Humana Press Inc, Totowa, NJ, 2000, 321-338.
131. Brabec, V.; Kasparkova, J.; Vrana, O.; Novakova, O.; Cox, J.W.; Qu, Y.; Farrell, N.; DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent; Biochemistry, 1999, 38, 6781-6790.
132. Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R.D.; Howell, S.B.; The role of DNA mismatch repair in platinum drug resistance; Cancer Res., 1996, 56, 4881-4886.
133. Aebi, S.; Fink, D.; Gordon, R.; Kim, H.K.; Zheng, H.; Fink, J.L.; Howell, S.B.; Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells; Clin. Cancer Res., 1997, 3, 1763-1767.
134. Johnson, S.W.; Ferry, K.V.; Hamilton, T.C.; Recent insights into platinum drug resistance in cancer; Drug Resist. Updates, 1998, 1, 243-254.
135. Drummond, J.T.; Anthoney, A.; Brown, R.; Modrich, P.; Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line; J. Biol. Chem., 1996, 271, 19645-19648.
136. Fink, D.; Nebel, S.; Aebi, S.; Nehme, A.; Howell, S.B.; Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin; Int. J. Oncol., 1997, 11, 539-542.
137. Ferry, K.V.; Fink, D.; Johnson, S.W.; Nebel, S.; Hamilton, T.C.; Howell, S.B.; Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells; Biochem. Pharmacol., 1999, 57, 861-867.
138. Calsou, P.; Frit, P.; Salles, B.; Double strand breaks in DNA inhibit nucleotide excision repair in vitro; J. Biol. Chem., 1996, 271, 27601-27607.
139. Frit, P.; Calsou, P.; Chen, D.J.; Salles, B.; Ku70/Ku80 protein complex inhibits the binding of nucleotide excision repair proteins on linear DNA m vitro; J. Mol. Biol., 1998, 284, 963-973.
140. Frit, P.; Canitrot, Y.; Muller, C.; Foray, N.; Calsou, P.; Marangoni, E.; Bourhis, J.; Salles, B.; Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dic hlorodiammineplatinum(II): Role of Ku autoantigen; Mol. Pharmacol., 1999, 56, 141-146.
141. Bhattacharyya, A.; Ear, U.S.; Koller, B.H.; Weichselbaum, R.R.; Bishop, D.K.; The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin; J. Biol. Chem., 2000, 275, 23899-23903.
142. Caldecott, K.; Jeggo, P.; Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents; Mutation Res., 1991, 255, 111-121.
143. De Silva, I.U.; McHugh, P.J.; Clingen, P.H.; Hartley, J.A.; Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cis-platin; Nucleic Acids Res., 2002, 30, 3848-3856.
144. Cummings, M.; Higginbottom, K.; McGurk, C.J.; Wong, O.G.-W., Koberle, B.; Oliver, R.T.D.; Masters, J.R.; XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: Role of ERCC1 in homologous recombination repair; Biochem. Pharmacol., 2006, 72, 166-175.
145. Selvakumaran, M.; Pisarcik, D.A.; Bao, R.; Yeung, A.T.; Hamilton, T.C.; Enhanced cispla-tin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines; Cancer Res., 2003, 63, 1311-1316.
146. Brabec, V.; Kasparkova, J.; Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs; Drug Resist. Updates, 2005, 8, 131-146.
147. Jung, Y.; Lippard, S.J.; Direct cellular responses to platinum-mduced DNA damage; Chem. Rev., 2007, 107, 1387-1407.
148. Teletchéa, S.; Komeda, S.; Teuben, J.-M., Elizondo-Riojas, M.A.; Reedijk, J.; Kozelka, J.; A pyrazolato-bridged dinuclear platinum(II) complex induces only minor distortions upon DNA-binding; Chem. Eur. J., 2006, 12, 3741-3753.
149. Komeda, S.; Lutz, M.; Spek, A.L.; Yamanaka, Y.; Sato, T.; Chikuma, M.; Reedijk, J.; A novel isomerization on interaction of antitumor-active azole-bridged dinuclear platinum(II) complexes with 9-ethylguanine. Platinum(II) atom migration from N2 to N3 on 1, 2, 3-triazole; J. Am. Chem. Soc., 2002, 124, 4738-4746.
150. Komeda, S.; Kalayda, G.V.; Lutz, M.; Spek, A.L.; Yamanaka, Y.; Sato, T.; Chikuma, M.; Reedijk, J.; New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin; J. Med. Chem., 2003, 46, 1210-1219.
151. Komeda, S.; Bombard, S.; Perrier, S.; Reedijk, J.; Kozelka, J.F.; Kinetic study of azole-bridged dinuclear platinum(II) complexes reacting with a hairpin-stabilized doublestranded oligonucleotide; J. Inorg. Biochem., 2003, 96, 357-366.
152. Spiegel, K.; Magistrato, A.; Carloni, P.; Reedijk, J.; Klein, M.L.; Azole-bridged diplatinum anticancer compounds. Modulating DNA flexibility to escape repair mechanism and avoid cross resistance; J. Phys. Chem. B, 2007, 111, 11873-11876.
153. Madhusudan, S.; Hickson, I.D.; DNA repair inhibition: a selective tumour targeting strategy; Trends Mol. Med., 2005, 11, 503-511.
154. Hubscher, U.; Maga, G.; Spadari, S.; Eukaryotic DNA polymerases; Annu. Rev. Biochem., 2002, 71, 133-163.